FAQ - Cannabinoid Hyperemesis Syndrome (2024)

What is Cannabinoid Hyperemesis Syndrome (CHS)?

CHS is a condition characterized by recurring episodes of severe nausea, vomiting, and abdominal pain. It is associated with chronic and heavy cannabis use, often developing after months or years of daily use. The exact cause is not fully understood but is believed to involve disruptions in the body's endocannabinoid system, which regulates various physiological processes including appetite, pain sensation, and nausea.

What are the symptoms of CHS?

CHS typically progresses through three phases:

1. Prodromal Phase: This phase can last for months or even years and is characterized by:

  • Morning nausea

  • Abdominal discomfort

  • A fear of vomiting

  • Increased cannabis use to alleviate symptoms

2. Hyperemesis Phase: This phase involves intense and debilitating symptoms, including:

  • Severe nausea and vomiting that can persist for hours

  • Abdominal pain, particularly in the upper abdomen

  • Dehydration

  • Compulsive hot showering or bathing for temporary relief

3. Recovery Phase: This phase begins with cannabis abstinence and can last for days, weeks, or months. Symptoms gradually subside and normal eating habits resume. However, relapse is possible if cannabis use is resumed.

Can CHS occur even if I stop using cannabis?

While CHS is primarily associated with active cannabis use, there are rare cases where symptoms emerge or persist shortly after cessation. This could be due to THC, the psychoactive component of cannabis, being stored in body fat and released over time, potentially triggering a delayed reaction.

What causes CHS?

The exact cause of CHS is not definitively known, but several theories exist, including:

  • Dysregulation of the Endocannabinoid System: Chronic cannabis use, particularly high-potency strains, may disrupt the balance of the endocannabinoid system, leading to altered signaling in areas of the brain involved in nausea and vomiting.

  • THC Toxicity: Accumulation of THC in body fat can lead to prolonged exposure and potential toxicity, contributing to CHS symptoms.

  • Genetic Predisposition: Recent research suggests that certain genetic mutations may increase susceptibility to developing CHS. These mutations affect genes related to cannabinoid metabolism, dopamine signaling, and the TRPV1 receptor (involved in pain and heat sensation).

How is CHS diagnosed?

Diagnosing CHS can be challenging as its symptoms mimic other conditions. A thorough medical history, including cannabis use patterns, is crucial. Doctors may also rule out other potential causes through physical exams and laboratory tests.

What are the treatment options for CHS?

The primary and most effective treatment for CHS is complete cannabis abstinence. Other measures include:

  • Intravenous Fluids: To combat dehydration caused by severe vomiting.

  • Antiemetics: Medications to reduce nausea and vomiting.

  • Benzodiazepines: For anxiety and agitation.

  • Topical Capsaicin: Application of capsaicin cream to the abdomen can provide temporary relief, perhaps by stimulating the TRPV1 receptor.

  • Tricyclic Antidepressants: Medications like amitriptyline have shown promise in preventing CHS episodes.

Can CBD use cause CHS?

While CHS is typically linked to THC, there are emerging reports of individuals experiencing CHS-like symptoms after using CBD products. This is likely due to CBD's interaction with the TRPV1 receptor and the potential for CBD to be converted into THC during heating processes like vaping. However, more research is needed to establish a definitive link between CBD and CHS.

What are the long-term implications of CHS?

CHS itself is not typically associated with long-term health problems and symptoms generally resolve with cannabis abstinence. However, the genetic mutations linked to CHS susceptibility may increase the risk of developing other conditions, including:

  • Addiction

  • Psychiatric disorders (anxiety, depression, psychosis)

  • Chronic pain

  • Cardiovascular disease

  • Type II diabetes

  • Dementia

Early diagnosis of CHS and genetic counseling can help individuals understand and manage these potential risks.

Source: Russo, E. B. & Whiteley, V. L. Cannabinoid hyperemesis syndrome: genetic susceptibility to toxic exposure. Front. Toxicol. 6, 1465728 (2024).

Disclaimer: This article is intended for informational purposes only and does not constitute medical advice. Always consult a healthcare professional for medical diagnosis or treatment recommendations.

Previous
Previous

UNRAVELING THE MYSTERY OF CHS: AN UNTAMED FRONTIER IN CANNABINOID SCIENCE

Next
Next

From Fast Food To Gourmet: Hemp Takes The Leap From Hotdogs To Haute Cuisine